Inhaled nicotine reaches the brain within seconds. That speed teaches the brain to connect a puff with a change in feeling. The calm may be real, but in dependence much of it can be relief from withdrawal, not treatment for anxiety, ADHD, depression, or trauma.
The title says ten seconds. Biology is less tidy. Nicotine from a cigarette reaches the brain within seconds.1 The lag from a puff to the brain is usually estimated at 10 to 20 seconds.2 Imaging with radiolabeled nicotine shows that brain nicotine then climbs gradually across the whole cigarette rather than spiking with each individual puff.3 Puff depth, product design, inhalation, metabolism, and prior use all matter.
Speed matters because the brain is a rapid learner. A tense thought, a doorway, coffee, a friend, and a puff can become linked before the person experiences it as a deliberate choice.
What matters most
- Nicotine can briefly improve withdrawal-related irritability or concentration, then falling levels help create the next urge.
- Cigarette smoke adds thousands of chemicals, more than 7,000 in all, and most of the lethal disease risk.4 Nicotine drives dependence but is not the main cause of smoking-related cancer.5
- On average, quitting is not associated with worsening mental health and may improve anxiety, depression, stress, and quality of life, but it does not replace psychiatric treatment.
- Smoke, not nicotine, induces the liver enzyme CYP1A2. Stopping cigarettes can raise clozapine and olanzapine levels, so the prescriber needs to know promptly.
- Vaping removes combustion but can still deliver high nicotine, reinforce frequent use, and expose users to uncertain long-term risk.
The receptor and the reward loop
Nicotine resembles acetylcholine enough to activate nicotinic acetylcholine receptors. Receptors containing alpha4 and beta2 subunits are especially important, but they are not the only ones involved. Activation can increase dopamine signaling in reward and learning circuits. Dopamine is not simply happiness. It helps the brain mark a cue as important and worth repeating.
In a PET study of 11 tobacco-dependent smokers, one to two puffs of a cigarette occupied about 50% of alpha4beta2 receptor sites for roughly three hours, and a full cigarette or more occupied more than 88%.6 That striking finding is not a complete explanation of dependence. Nicotine also acts on other receptor subtypes and circuits, and behavior is shaped by stress, routines, social setting, marketing, and access.
After activation, receptors can become temporarily desensitized. With chronic exposure, the brain may increase high-affinity receptor binding sites. It is tempting to say “more receptors equal more craving,” but dependence is not a receptor head count. Desensitization, adaptation, learning, withdrawal, and context work together.
Nicotine’s elimination half-life is about two hours, with substantial person-to-person variation.7 Levels fall between cigarettes and overnight. Irritability, restlessness, low mood, difficulty concentrating, hunger, or craving can appear, then improve after another dose. There is no scientifically useful universal count of daily “mini-withdrawals.” Some users smoke in clusters, some vape almost continuously, and metabolism differs.
What smoke adds
Nicotine maintains dependence. Burned tobacco creates most of the disease burden. Combustion exposes the lungs and bloodstream to carbon monoxide, fine particles, carcinogens, and toxic gases. This distinction matters because a safer nicotine medicine is not equivalent to smoking. It does not make nicotine harmless, especially for youth, pregnancy, poisoning risk, or cardiovascular symptoms.
Tobacco smoke also appears to inhibit monoamine oxidase, or MAO, enzymes in the brain. PET studies found about 40% lower brain MAO-B8 and about 28% lower brain MAO-A9 in smokers than in nonsmokers. MAO helps break down dopamine and other monoamines, so reduced activity could contribute to reinforcement. The responsible smoke chemicals, timing, and exact contribution to human dependence remain uncertain. Nicotine alone does not explain every effect of a cigarette.
Two smoke effects with similar initials should not be confused. MAO inhibition is a possible contributor to reinforcement in the brain. CYP1A2 induction changes how the liver clears certain medicines. The first is not a reason to treat cigarettes as antidepressants, and the second comes from combustion products rather than nicotine itself.
Carbon monoxide adds another misleading contrast. After smoking stops, carbon monoxide exposure drops quickly, but withdrawal can make the person feel worse before they feel better. Immediate discomfort does not mean the body needs smoke for oxygen or health. It means the dependence and recovery clocks are moving at different speeds.
Why a cigarette can feel calming
Psychologist Andrew Parrott described a deprivation-reversal model:10 smoking can remove withdrawal discomfort that smoking dependence helped create. The relief feels like stress treatment because the contrast is immediate. Then nicotine falls and the cycle restarts.
The word “only” in the title needs qualification. In a dependent person, much perceived calming may be withdrawal reversal. Conditioning, ritual, expectations, stepping away from a conflict, slower breathing, social contact, and acute nicotine effects can also contribute. A cigarette may feel useful while still worsening the long-term loop.
Consider two moments that can feel identical. In the first, a person with panic disorder becomes anxious, smokes, leaves the stressful room, and breathes more slowly outside. In the second, nicotine has fallen during a long meeting, withdrawal adds restlessness, and smoking removes it. Both people report, honestly, that the cigarette helped. Only the second story is mainly deprivation reversal, and even there ritual and escape may contribute. That is why treatment should address both nicotine dependence and any independent anxiety.
Nicotine can also sharpen attention briefly, particularly when it reverses withdrawal-related difficulty concentrating. That effect does not mean the brain performs better across the whole day. The user may be moving between withdrawal and temporary normalization. Sleep disruption, time spent obtaining or using nicotine, and cue-driven distraction belong in the full accounting.
The strongest population evidence is encouraging. A Cochrane review found that people who stopped smoking did not have worse anxiety, depression, stress, positive affect, or quality of life on average than people who continued. Many measures showed small to moderate improvement.11 Certainty ranged from very low to moderate because much of the evidence was observational and people who quit successfully may differ from those who continue.
The comparison was not simply the hour after the last cigarette. Many studies assessed mental health after weeks or months, when acute withdrawal had eased. That distinction explains how both statements can be true: quitting can temporarily feel emotionally rough, and people who remain quit can have equal or better mental health later.
Return to smoking complicates studies. A person who relapses may be classified differently across analyses, and worsening depression can both precede and follow relapse. Researchers cannot blind someone to whether they stopped smoking. The evidence therefore supports reassurance and monitoring, not a promise that every symptom will improve.
Quitting is not an antidepressant for everyone. Withdrawal can temporarily worsen mood, sleep, and concentration. Someone with major depression, panic disorder, bipolar disorder, PTSD, or schizophrenia still deserves direct treatment. New suicidal thinking, mania, psychosis, or inability to function needs prompt clinical help.
Smoking and mental health
In 2019, the most recent year for which CDC publishes this comparison, U.S. adults reporting a mental-health condition had a past-month cigarette-smoking prevalence of 27.2%, compared with 15.8% among those without one.12 Overall adult smoking has continued to fall since then, so current absolute rates are likely lower even if the gap persists. Rates differ by diagnosis, severity, age, poverty, housing, and setting. Higher prevalence does not prove that smoking caused the condition or that the condition caused smoking.
Depression and anxiety
Shared genetic risk, social disadvantage, trauma, withdrawal, and bidirectional effects may all contribute. Nicotine may briefly change attention or arousal. Smoking can also worsen sleep, create repeated withdrawal, restrict activity, and add illness and financial stress. The fact that symptoms improve after a cigarette cannot distinguish drug treatment from withdrawal relief.
ADHD
People with ADHD smoke at higher rates. Impulsivity, reward sensitivity, concentration difficulties, co-occurring conditions, and self-medication attempts may contribute. Nicotine is not a safe or approved ADHD treatment. A brief attention effect does not match the safety, dosing, or evidence of clinician-managed ADHD care.
PTSD
Cues, hyperarousal, avoidance, trauma-related distress, and high co-occurrence with alcohol or other substances can make smoking deeply embedded in a day. Trauma-informed cessation should preserve choice and teach ways to respond to arousal without making treatment contingent on perfect emotional stability.
Bipolar disorder
Smoking is common, and mood episodes can change use, sleep, spending, and risk-taking. Withdrawal symptoms can be confused with depression or agitation. A quit plan should include mood monitoring and prompt contact for decreased need for sleep, racing thoughts, dangerous impulsivity, or suicidal depression.
Schizophrenia-spectrum disorders
Very high smoking rates have been reported in many clinical populations, but estimates depend on country, setting, and era. Nicotine effects, cognition, poverty, institutional culture, and medication metabolism may all matter. Smoking contributes to the large physical-health burden, but it does not explain the entire mortality gap. Effective cessation treatment should be offered, with medication monitoring rather than therapeutic pessimism.
The clinical pearl that can prevent toxicity
Polycyclic aromatic hydrocarbons in smoke induce CYP1A2, a liver enzyme. Nicotine is not the main inducer. When cigarette smoking stops or drops sharply, enzyme induction fades and blood levels of some medicines can rise.13
This is especially important for clozapine and olanzapine. Higher exposure can produce excessive sedation, dizziness, confusion, low blood pressure, movement problems, seizures, or other toxicity. Caffeine is also metabolized partly through CYP1A2, so the same coffee routine may feel stronger after smoking stops.
Other CYP1A2 substrates can matter, but the size and clinical importance differ. The key action is to report the change in smoke exposure, not to memorize a drug list. Tell the prescriber whether cigarettes stopped completely, dropped sharply, restarted, or were replaced by vaping or NRT. A temporary smoke-free hospitalization counts. Guidance differs on how urgently a brief admission matters. UK regulatory advice notes that CYP1A2 induction takes about a week to fade, so dose adjustment is often unnecessary for a short hospital stay.13 Clozapine-specific guidance advises earlier review, because mean plasma clozapine concentrations rise substantially, on the order of 70%, after smoking stops.14 Let the prescriber, not the patient, make that call.
The reverse change matters too. Restarting cigarettes can lower medicine exposure again as enzyme induction returns. Symptoms may worsen if a carefully adjusted dose becomes too low. Monitoring should continue through relapse or switching, without blame.
Switching from cigarettes to nicotine replacement or exclusive vaping can remove smoke induction even while nicotine continues. Hospital admission to a smoke-free unit can cause the same abrupt change. Contact the prescriber promptly when smoking changes. Do not adjust clozapine, olanzapine, or another medicine on your own. Clinicians may need symptom review, drug levels when appropriate, and planned dose monitoring.
Why dependence can be so persistent
Rapid delivery gives the brain many closely timed lessons. A cigarette follows waking, driving, meals, work breaks, alcohol, conflict, or relief. Withdrawal adds negative reinforcement: use removes an unpleasant state. Easy availability and social cues keep the lesson visible.
A quit attempt is an event. Long-term abstinence is a changing process. An unsupported attempt may succeed, but a universal “5% chance” is not defensible without a population, follow-up period, and abstinence definition. Counseling and medication improve the odds, and needing repeated attempts is common rather than diagnostic of weak motivation.15
Dependence is not measured only by quantity. Time to first use after waking, difficulty staying in a smoke-free place, using while ill, waking at night, repeated unsuccessful attempts, and continued use despite harm can reveal how tightly nicotine organizes the day. A person who uses fewer cigarettes may still have strong cue-driven dependence, while another may need a different treatment intensity.
This is why treatment should match the pattern, not compete over who smokes more. A morning urge, continuous vaping, and alcohol-triggered smoking may need different medication coverage and cue plans.
The goal is freedom from the pattern, not a more impressive withdrawal story.
Psychiatric comorbidity can add triggers and medication complexity, but it should not become a reason to withhold treatment. Coordination is the answer.
What withdrawal looks like when the loop is interrupted
Craving, irritability, restlessness, anxiety, low mood, increased appetite, sleep change, and difficulty concentrating are common. Symptoms often begin within the first day, are strongest during the first several days, and then ease over weeks, but no calendar fits everyone. Cues can trigger a sharp urge long after the continuous physical symptoms have improved.
This distinction matters for mental health. A brief wave that follows coffee or driving may be a learned cue. Low mood that deepens, persists, or includes hopelessness may need a depression assessment. Decreased need for sleep, racing thoughts, or escalating impulsivity may suggest mania rather than ordinary withdrawal. Hallucinations or severe disorganization are not routine nicotine withdrawal.
Nicotine replacement can reduce withdrawal while a person changes the behavior loop. A long-acting patch provides steadier coverage; gum or lozenges can address breakthrough urges. Varenicline changes receptor signaling so cigarettes become less reinforcing and withdrawal is reduced. Bupropion also reduces withdrawal for some adults. These options are explained with exact instructions and cautions in Quit Kit.
Quitting does not remove every coping ritual at once. A planned break, a short walk, paced breathing, cold water, texting someone, or a different route can preserve the useful pause while separating it from smoke. These are not cures for panic, PTSD, or major depression. They are replacements for one learned link.
Teens and young adults
The brain continues developing through adolescence into the mid-to-late twenties, with no switch at age 25. Nicotine exposure during this period can support dependence and may affect attention, learning, sleep, and mood. Human evidence is complicated by shared risk, other substance use, and social context, so one exposure should not be described as permanently changing a brain.
Flavors, small devices, social media, peer use, and concealability change exposure opportunities. Early dependence can look like using soon after waking, difficulty getting through class or work, irritability without the device, or using more than intended.
Same Hijack, Sleeker Delivery: Vaping
Nicotine salts often combine nicotine with an acid such as benzoic acid. A lower-pH aerosol may feel less harsh at high nicotine concentration, which lets a product carry more nicotine without becoming intolerable.16 Delivered nicotine still depends on concentration, device power, coil, puff length, inhalation, and user experience. A “5%” label is a concentration, not a universal cigarette equivalent.
The 2025 National Youth Tobacco Survey, released in 2026, estimated current e-cigarette use in the past 30 days among 5.2% of U.S. middle and high school students, about 1.44 million young people. Prevalence was 7.1% in high school and 2.6% in middle school. Among current users, 27.5% used daily, 41.2% used on at least 20 of 30 days, 89.4% used flavored products, and 66.3% usually used disposables. Use had fallen substantially from 2022, but frequent use among current users remained concerning.17
“Current use” means any use in the prior 30 days, so it includes very different patterns. Daily use and use on at least 20 days help show intensity among current users. A falling national prevalence and high-frequency use can coexist. Neither statistic tells a parent how dependent one young person is.
Survey responses can miss young people not attending school and may be affected by recall or willingness to disclose. They remain the best current national school-based estimates, not a complete census.
Studies link youth vaping with depression, anxiety, attention, and sleep problems. Many are cross-sectional, so they cannot establish whether vaping caused symptoms, symptoms increased vaping, or both share other causes.
The 2019 EVALI outbreak was strongly linked to vitamin E acetate in THC vaping products, especially from informal sources. That investigation should not be rewritten as proof that every vaping injury has one cause or that nicotine vaping is harmless.18
For an adult who already smokes, switching completely to vaping is generally expected to reduce exposure to many combustion toxicants. Long-term risk remains uncertain, and vaping is not harmless. The comparison does not justify use by youth, nonsmokers, or pregnant people. Dual use matters: adding vaping while continuing cigarettes may preserve much of smoking’s cardiovascular and cancer risk.
“Complete” is doing important work in that comparison. Smoking even a few cigarettes can retain substantial cardiovascular exposure, and people may compensate by inhaling more deeply or using both products in different settings. A person who vapes at home but smokes at work has changed the pattern without necessarily ending combustion. That is different from a time-limited switch that fully displaces cigarettes and leads toward stopping vaping.
Vaping can also erase natural stopping points. A cigarette ends. A small device can be used in a bedroom, car, bathroom, or between tasks, allowing many brief exposures. Some users wake at night to vape or reach for the device before getting out of bed. That pattern can make total intake hard to estimate from the label alone.
E-liquid nicotine can poison through swallowing or skin exposure, with particular danger to children. Nausea, vomiting, dizziness, sweating, confusion, weakness, or abnormal heart rate after a concentrated-liquid exposure deserves immediate Poison Control guidance. Severe symptoms, seizure, collapse, or breathing trouble require 911.
Long-term risk comparisons need a clear reference point. Cigarettes are extraordinarily dangerous, so “less harmful than smoking” can be true without meaning low risk. Aerosols can contain nicotine, ultrafine particles, metals, flavoring byproducts, and other chemicals. Products and devices evolve faster than decades-long disease studies can follow.
For a nonsmoker, starting to vape adds exposure rather than reducing it. For a smoker who fully switches, it can remove combustion. For a dual user, the net change depends on whether cigarettes truly fall to zero. These are different clinical questions and should not share one slogan.
Nicotine pouches contain no tobacco leaf but can deliver substantial nicotine. FDA has authorized marketing of some nicotine pouch products as tobacco products after population-risk review, and in June 2026 authorized 20 ZYN products to carry a specific modified-risk claim that using them instead of cigarettes lowers the risk of certain diseases.1920 Neither action is drug approval, a cessation indication, or a declaration that the products are safe. FDA’s own language is that there is no safe tobacco product and that quitting all tobacco would most benefit health. Oral irritation, nausea, dependence, and child poisoning are concerns. In the 2025 NYTS, 1.7% of students reported current pouch use, and 17.6% of current users used daily.17 Long-term oral and cardiovascular evidence is still developing.
Relief, Withdrawal, Relief Again
| Falling nicotine | Craving or irritability | Temporary reversal after use |
|---|---|---|
| Nicotine declines between cigarettes, overnight, or during a class or shift. | Attention narrows toward the product; tension, restlessness, or low mood may appear. A real anxiety or mood disorder may also be present. | A cigarette or vape relieves part of withdrawal and reinforces the cue. The underlying dependence remains. |
If you want out of the loop
The person is not the loop. The calm can be real while still being largely relief from withdrawal. Medication and behavioral support make quitting more likely, and psychiatric treatment can continue at the same time. Quit Kit gives exact, current instructions and a ranked evidence comparison.
Call 911 for severe chest pain, major breathing trouble, seizure, collapse, or inability to wake. Call or text 988 for a suicidal crisis, mania with danger, or psychosis. For nicotine poisoning or an uncertain exposure in the United States, call Poison Control at 1-800-222-1222.
Frequently asked questions
Does smoking really calm anxiety?
It can feel calming. In dependence, much of that change may be reversal of nicotine withdrawal. Ritual, expectation, and context also matter. Smoking is not treatment for an anxiety disorder.
Will quitting make depression or anxiety worse?
Withdrawal can temporarily worsen mood and irritability. On average, people who quit do not have worse mental health and may improve, but symptoms should be monitored and treated directly.
Is vaping safer than smoking?
Complete switching by an adult smoker likely reduces exposure to many combustion toxicants, but vaping is not harmless and long-term risk is uncertain. Dual use may preserve much smoking risk.
Why must my prescriber know when I stop smoking?
Smoke induces CYP1A2. Stopping can raise levels of clozapine, olanzapine, and some other medicines even if nicotine continues through a patch or vape. The prescriber may need to monitor and adjust safely.
Are nicotine pouches harmless?
No. They avoid smoke and tobacco leaf but can cause dependence, oral effects, nausea, and poisoning. FDA tobacco marketing authorization, including the 2026 modified-risk claim allowed for some ZYN products relative to cigarettes, is not medicine approval, a cessation indication, or a safety certificate.
If you plan to quit
This article is education, not individualized medical advice. Do not change psychiatric medicine, nicotine treatment, or smoking abruptly without appropriate support when a medication interaction or mental-health risk is possible.
Related reading on NP FADY
References
1. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303. https://pmc.ncbi.nlm.nih.gov/articles/PMC2928221/
2. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. 2014, chapter 5 (Nicotine). https://www.ncbi.nlm.nih.gov/books/NBK294308/
3. Rose JE, Mukhin AG, Lokitz SJ, et al. Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. Proc Natl Acad Sci USA. 2010;107(11):5190-5195. https://pubmed.ncbi.nlm.nih.gov/20212132/
4. Centers for Disease Control and Prevention. About Secondhand Smoke. https://www.cdc.gov/tobacco/secondhand-smoke/index.html
5. Truth Initiative. Re-thinking nicotine and its effects. 2019. https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf
6. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha4beta2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63(8):907-915. https://pmc.ncbi.nlm.nih.gov/articles/PMC2773659/
7. National Academies of Sciences, Engineering, and Medicine. Public Health Consequences of E-Cigarettes. 2018, chapter 4 (Nicotine). https://www.ncbi.nlm.nih.gov/books/NBK507191/
8. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379:733-736. https://pubmed.ncbi.nlm.nih.gov/8602220/
9. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA. 1996;93(24):14065-14069. https://pubmed.ncbi.nlm.nih.gov/8943061/
10. Parrott AC. Does cigarette smoking cause stress? Am Psychol. 1999;54(10):817-820. https://pubmed.ncbi.nlm.nih.gov/10540594/
11. Taylor GMJ, Lindson N, Farley A, et al. Smoking cessation for improving mental health. Cochrane Database Syst Rev. 2021;3:CD013522. 102 studies, more than 169,500 participants. https://www.cochrane.org/evidence/CD013522_does-stopping-smoking-improve-mental-health
12. Centers for Disease Control and Prevention. People with Behavioral Health Conditions Experience a Health Burden From Commercial Tobacco. Data source: 2019 National Survey on Drug Use and Health. https://www.cdc.gov/tobacco-health-equity/collection/behavioral-health-health-burden.html
13. UK Medicines and Healthcare products Regulatory Agency. Smoking and smoking cessation: clinically significant interactions with commonly used medicines. Published 11 December 2014; article date October 2009. https://www.gov.uk/drug-safety-update/smoking-and-smoking-cessation-clinically-significant-interactions-with-commonly-used-medicines
14. Lucas C, Martin J. Smoking and drug interactions. Aust Prescr. 2013;36:102-104. https://australianprescriber.tg.org.au/articles/smoking-and-drug-interactions.html
15. Centers for Disease Control and Prevention. Clinical Interventions to Treat Tobacco Use and Dependence Among Adults. https://www.cdc.gov/tobacco/hcp/patient-care-settings/clinical.html
16. R Street Institute. E-Cigarettes Composition: Nicotine Concentration and Nicotine Salts. https://www.rstreet.org/research/e-cigarettes-composition-nicotine-concentration-and-nicotine-salts/
17. U.S. Food and Drug Administration. Results from the Annual National Youth Tobacco Survey, 2025. Released 23 June 2026. https://www.fda.gov/tobacco-products/youth-and-tobacco/results-annual-national-youth-tobacco-survey-nyts
18. Centers for Disease Control and Prevention. Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury: United States, August 2019 to January 2020. MMWR. 2020;69(3):90-94. https://www.cdc.gov/mmwr/volumes/69/wr/mm6903e2.htm
19. U.S. Food and Drug Administration. Nicotine Pouch Products Authorized by FDA. Updated 2026. https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/nicotine-pouch-products-authorized-fda
20. U.S. Food and Drug Administration. FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim. 30 June 2026. https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-20-zyn-nicotine-pouches-be-marketed-specific-modified-risk-claim
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.